Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Multiple drugs, multiple targets

Amevive's Pole Position

Multiple drugs, multiple targets

While the exact cause of psoriasis is unknown, the approved systemic therapeutics as well as those in development show there is no lack of methods to attack the disease.

While the exact mechanism of action (MOA) has not been determined for Soriatane

Read the full 474 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers